Compass Pathways

As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect

Compass Pathways Recent News

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to at least two different standard antidepressant treatments.
Sponsored
What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of $125 million and the potential for an additional investment of up to $160 million if the warrants are
Sponsored
Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures
The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by its
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
(Part four of a four-part series) See previous stories: 
Understanding The Psilocybin Supply Chain: Every Production Method Explained
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin.
Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know
Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras.
Patents In The Psychedelics Space: Good Or Bad? It's Complicated, Here's What The Experts Say
Patents are the golden eggs of the booming psychedelic space.
Compass Pathways Partners With One Mind To Fund Rising Star Awards
Compass Pathways plc (NASDAQ:CMPS) and California-based non-profit organization One Mind partnered to sponsor three “2022 One Mind - COMPASS Rising Stars Awards.”
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of in
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pat
PA Psilocybin Bill Could Make The State A Frontrunner In Psychedelic Research, Aiding Vets & First Responders
The state of Pennsylvania is poised to become a leader in psychedelic research after a bill known as the Public Health Benefits of Psilocybin Act was introduced recently in the House of Representatives.
Psyched: California Psychedelics Bill Passes Second Committee, GH Research Closes $125M Series B, Study Shows Psilocybin Could Equal SSRI Results In Depression
A bill that would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychedelics in California passed the state Senate Health Committee. The bill will now be reviewed by the Senate Appropriations Committee, after which it would move to a Senate floor vote if approved.
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC
Compass Secures 2 New Patents In the midst of a public debate about the right use of patents in the psychedelics sector, Compass Pathways (NASDAQ: CMPS) was granted two new patents by the US Patent and Trademark Office.
Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY
These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments.
Compass 2020 Earnings Call: Strong Cash Positions And Advancing R&D
Compass Pathways (NASDAQ: CMPS), the first and only psychedelics company to list on a major U.S. stock exchange, released its financial results for the fourth quarter and year-end 2020.
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
The Horizons Psychedelic Stock Index ETF, As Told By Its Fund Manager
On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry. 
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
First Psychedelics ETF Debuts On NEO Exchange
The Horizons Psychedelic Stock Index ETF is now listed on Toronto’s NEO exchange under the symbol ‘PSYK.’ PSYK is the first exchange traded fund providing exposure to the burgeoning industry of medicinal psychedelics.
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved